Published in Transplantation on August 27, 2005
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Delayed graft function in the kidney transplant. Am J Transplant (2011) 2.06
Science of composite tissue allotransplantation. Transplantation (2008) 1.05
Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol (2011) 1.04
Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy (2011) 1.02
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
B cells and transplantation tolerance. Nat Rev Nephrol (2010) 0.97
Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics (2009) 0.93
Composite tissue allotransplantation of the face: Decision analysis model. Can J Plast Surg (2007) 0.91
Allopeptides and the alloimmune response. Cell Immunol (2007) 0.90
An important role for autoimmunity in the immunopathogenesis of chronic allograft rejection. Int J Immunogenet (2012) 0.86
New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs (2014) 0.84
New immunosuppressive agents in pediatric transplantation. Clinics (Sao Paulo) (2014) 0.82
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation (2006) 0.82
Current state of renal transplant immunosuppression: Present and future. World J Transplant (2012) 0.81
Antibody induction therapy in adult kidney transplantation: A controversy continues. World J Transplant (2012) 0.81
Clinical research in pediatric organ transplantation. Clinics (Sao Paulo) (2014) 0.81
Lymphodepletional strategies in transplantation. Cold Spring Harb Perspect Med (2013) 0.78
Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction. Am J Nephrol (2011) 0.77
Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int (2012) 0.77
The evolving role of alemtuzumab (Campath-1H) in renal transplantation. Drug Des Devel Ther (2009) 0.76
Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transpl Int (2013) 0.76
Comparison of the Effect of Alemtuzumab versus Standard Immune Induction on Early Kidney Allograft Function in Shiraz Transplant Center. Int J Organ Transplant Med (2015) 0.75
Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol. World J Transplant (2017) 0.75
Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients. Transplant Direct (2016) 0.75
Alemtuzumab and natalizumab: the monoclonal antibody story continues. Can J Infect Dis Med Microbiol (2006) 0.75
Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Oncotarget (2017) 0.75
Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks. Curr Transplant Rep (2016) 0.75
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Sequential therapies for proliferative lupus nephritis. N Engl J Med (2004) 5.96
Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med (2013) 5.62
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36
When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann Surg (2014) 2.23
Developing a comprehensive diagnostic and interventional nephrology program at an academic center. Am J Kidney Dis (2003) 1.99
Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis. Transplantation (2012) 1.89
The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant (2001) 1.88
Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes (2013) 1.71
Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend (2002) 1.65
Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant (2003) 1.64
Computer enhanced visual learning method to train urology residents in pediatric orchiopexy provided a consistent learning experience in a multi-institutional trial. J Urol (2010) 1.62
Intestinal transplantation for the treatment of neoplastic disease. J Surg Oncol (2005) 1.62
Heterotopic uterus transplantation in a swine model. Transplantation (2009) 1.59
Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol (2002) 1.57
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int (2005) 1.54
Transplantation of the abdominal wall. Lancet (2003) 1.51
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes (2013) 1.46
Two decades of pediatric kidney transplantation in a multi-ethnic cohort. Pediatr Transplant (2010) 1.45
Heterogeneity of cognitive trajectories in diverse older persons. Psychol Aging (2010) 1.44
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation (2002) 1.42
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl (2004) 1.42
Analysis of vascular access in intestinal transplant recipients using the Miami classification from the VIIIth International Small Bowel Transplant Symposium. Transplantation (2005) 1.40
Arteriovenous fistula creation: should US nephrologists get involved? Am J Kidney Dis (2003) 1.39
Living donor nephrectomy: University of Miami technique and current results. Arch Esp Urol (2010) 1.39
Lyme disease: knowledge, beliefs, and practices of physicians in a low-endemic area. Can Fam Physician (2012) 1.35
100 multivisceral transplants at a single center. Ann Surg (2005) 1.34
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation (2002) 1.32
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation (2004) 1.30
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 1.28
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol (2007) 1.26
Intestinal and multivisceral transplantation. World J Surg (2001) 1.25
Intestinal and multivisceral transplantation in children. Ann Surg (2006) 1.22
Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation (2006) 1.22
Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg (2011) 1.19
Does catheter insertion by nephrologists improve peritoneal dialysis utilization? A multicenter analysis. Semin Dial (2005) 1.17
Barriers to successful care for chronic kidney disease. BMC Nephrol (2005) 1.16
Allosensitization of islet allograft recipients. Transplantation (2007) 1.13
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation (2007) 1.13
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation (2002) 1.11
Peritoneal dialysis underutilization: the impact of an interventional nephrology peritoneal dialysis access program. Semin Dial (2003) 1.08
Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg (2010) 1.08
TNF-alpha, TGF-beta, IL-10, IL-6, and INF-gamma alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops: Part IV. Hum Immunol (2004) 1.07
Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol (2010) 1.07
Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res (2006) 1.06
Graft-versus-host disease after intestinal and multivisceral transplantation. Transplantation (2011) 1.06
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Intrahepatic biliary strictures after liver transplantation. J Hepatobiliary Pancreat Surg (2006) 1.05
Disparities among Blacks, Hispanics, and Whites in time from starting dialysis to kidney transplant waitlisting. Transplantation (2013) 1.04
Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation (2008) 1.03
Donor intracaval thrombus formation and pulmonary embolism after simultaneous piggyback liver transplantation and aortic valve replacement. Clin Transplant (2003) 1.02
Intestinal transplantation in children: a summary of clinical outcomes and prognostic factors in 108 patients from a single center. J Gastrointest Surg (2005) 1.01
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr (2006) 1.01
Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation (2005) 1.00
Minimization and withdrawal of steroids in pancreas and islet transplantation. Transpl Int (2008) 0.99
The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 0.99
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 0.99